DEF 14A: Iris Acquisition Corp Seeks Extension to Complete Business Combination Amidst Setbacks

Iris Acquisition Corp is seeking stockholder approval to extend the deadline for completing a business combination to December 31, 2024, due to recent challenges with its proposed merger with Liminatus Pharma.

Summary

• Iris Acquisition Corp is holding a special meeting on September 5, 2024, to vote on a proposal to extend the date by which it must complete a business combination from September 9, 2024, to December 31, 2024.
• The company's board believes there is insufficient time to complete the previously announced business combination with Liminatus Pharma before the current deadline.
• A related proposal seeks approval to adjourn the special meeting if necessary to solicit additional proxies.
• Public stockholders have the option to redeem their shares for a pro rata portion of the trust account, estimated at approximately $11.02 per share at the time of the special meeting, regardless of their vote on the extension amendment.
• If the extension is approved, the sponsor has agreed to loan the company the lesser of $17,000 or $0.06 per month for each public share that is not redeemed, potentially increasing the redemption amount per share at the time of the business combination or liquidation to approximately $11.20.
• If the extension is not approved, the company will liquidate, and warrants will expire worthless.
• The sponsor and insiders will not receive any funds from the trust account in the event of liquidation.
• Approval of the extension amendment requires the affirmative vote of at least 65% of the outstanding shares of common stock.
• The company has been notified by Nasdaq that the extension amendment does not comply with Nasdaq rules and could lead to suspension of trading or delisting.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is trying to extend its life to complete a business combination, there are significant risks and uncertainties, including potential delisting from Nasdaq and a terminated agreement with Targeted Diagnostics & Therapeutics, Inc.

Positives

• Stockholders have the option to redeem their shares for cash regardless of their vote on the extension.
• If the extension is approved, the sponsor's loan could increase the redemption amount per share.
• The board believes the business combination is in the best interest of stockholders and is seeking the extension to allow more time to complete it.

Negatives

• Failure to approve the extension will result in liquidation, with warrants expiring worthless.
• Nasdaq has indicated that the extension amendment could lead to suspension of trading or delisting.
• A terminated agreement with Targeted Diagnostics & Therapeutics, Inc. has introduced uncertainty regarding the business combination with Liminatus.

Risks

• The extension amendment contravenes Nasdaq rules and could lead to suspension of trading or delisting.
• The company may not be able to complete an initial business combination with a U.S. target company if it is subject to U.S. foreign investment regulations and review by CFIUS.
• A new 1% U.S. federal excise tax could be imposed on the company in connection with redemptions by the company of its shares that occur after December 31, 2022.
• The SEC has issued final rules and guidance relating to certain activities of SPACs, and the need for compliance with these rules and the guidance may cause the company to liquidate at an earlier time than it might otherwise choose.
• The company may be deemed to be an investment company for purposes of the 1940 Act, which would require the company to institute burdensome compliance requirements and severely restrict its activities.

Future Outlook

The company intends to hold another stockholder meeting prior to the Extended Date in order to seek stockholder approval of the business combination. The company will then continue to work to consummate the business combination by the Extended Date.

Management Comments

• Our Board believes stockholders should have an opportunity to evaluate the business combination.
• After careful consideration of all relevant factors, our Board has determined that the Extension Amendment is in the best interests of the Company and its stockholders.

Industry Context

This announcement is typical for SPACs approaching their initial business combination deadline. Many SPACs seek extensions to provide more time to find and complete a suitable merger target, especially given current market conditions and regulatory scrutiny.

Comparison to Industry Standards

• The redemption rate and potential liquidation of the trust account are key metrics to watch, as high redemption rates can make it more difficult for the SPAC to complete a business combination.
• Comparable SPACs, such as those nearing their deadlines, often face similar decisions regarding extensions and potential liquidations.
• The potential delisting from Nasdaq is a significant concern, as it could reduce liquidity and investor confidence, similar to other SPACs that have faced delisting warnings.

Stakeholder Impact

• Stockholders have the option to redeem their shares, potentially impacting the amount of funds available for a business combination.
• If the extension is not approved, stockholders will receive a pro rata share of the trust account, but warrants will expire worthless.
• Employees and management may be impacted by the outcome of the vote, as failure to complete a business combination will result in liquidation.

Next Steps

• Stockholders will vote on the extension amendment and adjournment proposal at the special meeting on September 5, 2024.
• If the extension is approved, the company will file an amendment to the charter and continue to seek a business combination.
• The company intends to hold another stockholder meeting prior to the Extended Date in order to seek stockholder approval of the business combination.

Key Dates

Keywords

business combination, extension amendment, redemption, liquidation, SPAC, trust account, Nasdaq, proxy statement, stockholders, Iris Acquisition Corp